Hence, these abovementioned findings collectively suggest the potential involvement of the lncRNA Sox2ot/miR-145/Egr1 axis in the occurrence and progression of AAA and speculate its potential role in the development of novel therapeutics for AAA. The gene discussed is EGR1; the disease is triple-A syndrome.